Opportunity Information: Apply for PAR 22 023
The National Institutes of Health (NIH) is soliciting R01 grant applications under PAR-22-023 titled "Multi-Disciplinary Collaborations to Understand Mechanisms of Systemic Immune Signaling and Inflammation in ADRD and its Progression (R01 Clinical Trial Not Allowed)." The opportunity targets research on how systemic (whole-body) immune responses and inflammation may contribute to Alzheimer disease (AD) and Alzheimer disease-related dementias (AD/ADRD), including their onset and progression. A central motivation is that, while brain-resident innate immune mechanisms (especially microglia) have been heavily studied in AD/ADRD, the role of immune activity originating outside the brain has received comparatively less attention, even though emerging findings suggest it could influence neurodegeneration through direct or indirect pathways.
The program is designed to build a stronger, more mature evidence base for this area by encouraging multi-disciplinary work that bridges neuroscience and immunology. NIH is explicitly trying to bring more immunology expertise into the AD/ADRD research ecosystem by supporting partnerships and new collaborations. Although individual projects are allowed, applications that meaningfully integrate neuroscientists with AD/ADRD expertise and immunologists are strongly encouraged, reflecting the initiative's emphasis on cross-field team science. The long-term intent is that results from these projects will establish foundations, tools, and mechanistic insights that can later be extended through standard investigator-initiated grants and other funding mechanisms.
This is an R01 mechanism, meaning it generally supports hypothesis-driven, mechanistic, and/or discovery-oriented research programs of substantial scope. The notice specifies "Clinical Trial Not Allowed," so proposed work should not include an NIH-defined clinical trial. In practice, that typically means the research can involve human data or samples if appropriately justified and compliant, but it cannot prospectively assign human participants to an intervention to evaluate health-related outcomes. The scientific focus is on mechanisms of systemic immune signaling and inflammation relevant to AD/ADRD biology, which could include studying immune-to-brain communication routes, peripheral inflammatory mediators, immune cell trafficking, interactions between systemic immunity and neurovascular or blood-brain barrier function, and how these processes might accelerate, modify, or correlate with neurodegenerative changes and dementia progression.
Eligibility is broad and includes a wide range of domestic and some non-domestic entities. Eligible applicants include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations and tribal governments that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); small businesses; and other organizations. The announcement also highlights additional eligible groups such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations). This breadth signals an intent to draw talent from diverse institutional settings and to broaden participation across underserved and specialized communities.
Administratively, the opportunity is categorized as a discretionary grant in the health funding activity area and is associated with CFDA numbers 93.853 and 93.866. The listed award ceiling is $499,000 (as provided in the source data). The original closing date in the provided listing is 2021-10-22, and the opportunity record creation date is 2021-08-06. Overall, the grant aims to catalyze and strengthen mechanistic research at the intersection of systemic immunology and neurodegeneration, positioning systemic immune signaling and inflammation as key, still underdeveloped areas for understanding and ultimately addressing AD/ADRD.Apply for PAR 22 023
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Multi-Disciplinary Collaborations to Understand Mechanisms of Systemic Immune Signaling and Inflammation in ADRD and its Progression (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853, 93.866.
- This funding opportunity was created on 2021-08-06.
- Applicants must submit their applications by 2021-10-22. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $499,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIH PAR-22-023 R01 - Systemic Immune Signaling and Inflammation in AD/ADRD (Clinical Trial Not Allowed)
What is this NIH funding opportunity?
This opportunity is a National Institutes of Health (NIH) solicitation for R01 grant applications under PAR-22-023 titled "Multi-Disciplinary Collaborations to Understand Mechanisms of Systemic Immune Signaling and Inflammation in ADRD and its Progression (R01 Clinical Trial Not Allowed)."
What is the main scientific goal of PAR-22-023?
The goal is to support research that clarifies how systemic (whole-body) immune signaling and inflammation may contribute to Alzheimer disease (AD) and Alzheimer disease-related dementias (AD/ADRD), including how these processes may influence disease onset and progression.
Why is NIH emphasizing systemic immunity and inflammation in AD/ADRD?
While brain-resident innate immune mechanisms (especially microglia) have been heavily studied in AD/ADRD, immune activity originating outside the brain has received comparatively less attention. NIH notes emerging findings suggesting systemic immune signaling and inflammation could influence neurodegeneration through direct or indirect pathways, and aims to strengthen the evidence base in this area.
What kinds of projects are encouraged under this program?
The program encourages hypothesis-driven, mechanistic, and/or discovery-oriented studies that investigate mechanisms of systemic immune signaling and inflammation relevant to AD/ADRD biology and progression. The emphasis is on building mechanistic insight and foundational evidence that can be extended later through other grant mechanisms.
What does "multi-disciplinary collaborations" mean in this announcement?
NIH is specifically trying to bridge neuroscience and immunology by bringing more immunology expertise into the AD/ADRD research ecosystem. Applications that meaningfully integrate neuroscientists with AD/ADRD expertise and immunologists are strongly encouraged, reflecting a focus on cross-field team science.
Are single-investigator or single-discipline projects allowed?
Yes. Individual projects are allowed, but the announcement strongly encourages projects that integrate AD/ADRD neuroscience expertise with immunology expertise, consistent with the program's emphasis on new partnerships and collaborations.
What grant mechanism is used for this opportunity?
This opportunity uses the NIH R01 mechanism, which generally supports research programs of substantial scope, including hypothesis-driven, mechanistic, and/or discovery-oriented work.
Are clinical trials allowed under this opportunity?
No. The notice specifies "Clinical Trial Not Allowed," meaning proposed work must not include an NIH-defined clinical trial.
What does "Clinical Trial Not Allowed" mean in practical terms?
Based on the description provided, research may involve human data or human samples if appropriately justified and compliant, but it cannot prospectively assign human participants to an intervention in order to evaluate health-related outcomes.
What scientific topics or mechanisms does the announcement highlight as relevant?
The solicitation highlights mechanistic work related to systemic immune signaling and inflammation in AD/ADRD, including examples such as immune-to-brain communication routes, peripheral inflammatory mediators, immune cell trafficking, interactions between systemic immunity and neurovascular or blood-brain barrier function, and how these processes might accelerate, modify, or correlate with neurodegenerative changes and dementia progression.
Is this opportunity focused only on Alzheimer disease (AD), or does it include other dementias?
It includes AD and Alzheimer disease-related dementias (AD/ADRD), with attention to both disease onset and progression.
What is the long-term intent of NIH for projects funded through this program?
NIH intends for results to establish foundations, tools, and mechanistic insights that can later be extended through standard investigator-initiated grants and other funding mechanisms.
Who is eligible to apply?
Eligibility is broad. Eligible applicants include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations and tribal governments that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); small businesses; and other organizations.
Are U.S. territories or non-U.S. (foreign) organizations eligible?
Yes. The opportunity listing highlights eligibility that includes U.S. territories or possessions and non-U.S. entities (foreign organizations).
Does the opportunity highlight any specific institution types as eligible?
Yes. In addition to the broad eligibility categories, it highlights Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, and regional organizations.
What funding activity area and grant type is this associated with?
The opportunity is categorized as a discretionary grant in the health funding activity area.
What CFDA numbers are associated with this opportunity?
The announcement is associated with CFDA numbers 93.853 and 93.866.
What is the listed award ceiling?
The listed award ceiling in the provided source data is $499,000.
What dates are provided in the opportunity listing?
The provided listing includes an opportunity record creation date of 2021-08-06 and an original closing date of 2021-10-22.
What problem or gap is NIH trying to address with this solicitation?
NIH aims to address the relative under-development of evidence and mechanistic understanding around immune activity outside the brain and how systemic immune signaling and inflammation may affect AD/ADRD neurodegeneration and progression, compared with the more heavily studied brain-resident innate immune mechanisms.
Browse more opportunities from the same category: Health
Next opportunity: 2022 Wood Innovations Funding Opportunity
Previous opportunity: Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 22 023
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 22 023) also looked into and applied for these:
| Funding Opportunity |
|---|
| Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase I: Data Analysis and Validation Centers (U24 Clinical trials not allowed) Apply for RFA HG 21 031 Funding Number: RFA HG 21 031 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase I: Data Analysis and Validation Centers (U01 Clinical trials not allowed) Apply for RFA HG 21 030 Funding Number: RFA HG 21 030 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase 1: Data Production Research and Development Centers (UM1)(Clinical trials not allowed) Apply for RFA HG 21 029 Funding Number: RFA HG 21 029 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Reducing Racial and Ethnic Healthcare Disparities in Chronic Conditions by Dissemination and Implementation of Patient Centered Outcomes Research (PCOR) Evidence (R18) Apply for RFA HS 22 001 Funding Number: RFA HS 22 001 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $1,500,000 |
| Resource Center for Tribal Epidemiological Centers (RC-TEC) (U24 Clinical Trial Not Allowed) Apply for RFA MD 21 003 Funding Number: RFA MD 21 003 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Clinical and Biological Measures of TBI-related Dementia Including Chronic Traumatic Encephalopathy (R01 Clinical Trial Not Allowed) Apply for PAR 22 024 Funding Number: PAR 22 024 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Creating an Educational Nexus for Training in Experimental Rigor (CENTER) (UC2 Clinical Trial Not Allowed) Apply for RFA NS 21 009 Funding Number: RFA NS 21 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Dementia Care and Caregiver Support Intervention Research (R01 Clinical Trial Required) Apply for PAR 21 307 Funding Number: PAR 21 307 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pragmatic Trials for Dementia Care and Caregiver Support (R61/R33 Clinical Trial Required) Apply for PAR 21 308 Funding Number: PAR 21 308 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Feasibility Studies that Explore Healthy and Diseased Temporomandibular Joints (TMJ) using Single Cell Multi-Omic Analyses (UH2/UH3 Clinical Trial Not Allowed) Apply for RFA DE 22 005 Funding Number: RFA DE 22 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed) Apply for PAR 21 316 Funding Number: PAR 21 316 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Genome Sequencing Center for the Gabriella Miller Kids First Pediatric Research Program (U24 Clinical Trial Not Allowed) Apply for RFA RM 21 013 Funding Number: RFA RM 21 013 Agency: National Institutes of Health Category: Health Funding Amount: $7,200,000 |
| Selectively Target Technology Development to Understand How Changes or Dysfunction at the Capillary, Arterioles, and Small Lymphatic Vessels Level Can Have Long-term Impact on AD/ADRD (R01 Clinical Trial Not Allowed) Apply for PAR 22 026 Funding Number: PAR 22 026 Agency: National Institutes of Health Category: Health Funding Amount: $499,000 |
| Deciphering Immune-CNS interactions in HIV utilizing in-vitro and in-vivo model systems (R21 Clinical Trial Not Allowed) Apply for RFA MH 21 251 Funding Number: RFA MH 21 251 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Deciphering Immune-CNS interactions in people living with HIV on Anti-Retroviral therapy (R01 Clinical Trial Optional) Apply for RFA MH 21 250 Funding Number: RFA MH 21 250 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HIV Prevention and Alcohol (R01 Clinical Trials Optional) Apply for RFA AA 21 016 Funding Number: RFA AA 21 016 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| HIV Prevention and Alcohol (R34 Clinical Trials Optional) Apply for RFA AA 21 017 Funding Number: RFA AA 21 017 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| Blueprint Medtech: Small Business Translator (U44 - Clinical Trial Optional) Apply for PAR 21 282 Funding Number: PAR 21 282 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Continued Development of the Gabriella Miller Kids First Pediatric Data Resource Center (U2C Clinical Trial Not Allowed) Apply for RFA RM 21 014 Funding Number: RFA RM 21 014 Agency: National Institutes of Health Category: Health Funding Amount: $4,000,000 |
| Tanzania Malaria Case Management Activity (TMCM) Apply for RFI 621 21 HO 001 Funding Number: RFI 621 21 HO 001 Agency: Tanzania USAID-Dar es Salaam Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 22 023", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.